Premium
Treg Cell Function in Rheumatoid Arthritis Is Compromised by CTLA‐4 Promoter Methylation Resulting in a Failure to Activate the Indoleamine 2,3‐Dioxygenase Pathway
Author(s) -
Cribbs Adam P.,
Kennedy Alan,
Penn Henry,
Read Jordan E.,
Amjadi Parisa,
Green Patricia,
Syed Khaja,
Manka Szymon W.,
Brennan Fionula M.,
Gregory Bernard,
Williams Richard O.
Publication year - 2014
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.38715
Subject(s) - indoleamine 2,3 dioxygenase , dna methylation , epigenetics , methylation , biology , chromatin immunoprecipitation , promoter , bisulfite sequencing , gene , t cell , chromatin , regulation of gene expression , gene expression , cancer research , microbiology and biotechnology , immunology , immune system , genetics , tryptophan , amino acid
Objective Functionally impaired Treg cells expressing abnormally low levels of CTLA‐4 have been well documented in rheumatoid arthritis (RA). However, the molecular defect underlying this reduced expression is unknown. The aims of this study were to assess the role of DNA methylation in regulating CTLA‐4 expression in Treg cells isolated from RA patients and to elucidate the mechanism of their reduced suppressor function. Methods CTLA‐4 expression in Treg cells from RA patients and healthy controls was measured by quantitative polymerase chain reaction (PCR) and flow cytometry. Methylation of the CTLA‐4 gene promoter was analyzed by bisulfite‐specific PCR, followed by sequencing. Methylation‐dependent transcriptional activity of the CTLA‐4 gene promoter was measured by luciferase assay, and NF‐AT binding to the CTLA‐4 gene promoter was determined by chromatin immunoprecipitation. The role of CTLA‐4 expression in controlling Teff cells was analyzed using an autologous mixed lymphocyte reaction. Results Down‐regulation of CTLA‐4 expression in Treg cells from RA patients was caused by methylation of a previously unidentified NF‐AT binding site within the CTLA‐4 gene promoter. As a consequence, Treg cells were unable to induce expression and activation of the tryptophan‐degrading enzyme indoleamine 2,3‐dioxygenase (IDO), which in turn resulted in a failure to activate the immunomodulatory kynurenine pathway. Conclusion We show for the first time that epigenetic modifications contribute to defective Treg cell function in RA through an inability to activate the IDO pathway. Therefore, this study sets a precedent for investigating potential therapeutic strategies aimed at reinforcing the IDO pathway in RA patients.